Abstract
Introduction
The objective of this work is to compare the effectiveness of hormonal treatment (luteinizing hormone-releasing hormone agonists and/or antiandrogens) as an early or as a deferred intervention for patients with locally advanced prostate cancer (LAPC) and/or asymptomatic metastasis.
Materials and methods
Systematic review of trials published in 1950–2007. Sources included MEDLINE and bibliographies of retrieved articles. Eligible trials included adults with a history of LAPC who are not suitable for curative local treatment of prostate cancer. We retrieved 22 articles for detailed review, of which 8 met inclusion criteria. The Veterans Administration Cooperative Urological Research Group suggested that delaying hormonal therapy did not compromise overall survival and that many of the patients died of causes other than prostate cancer. In European Organisation for Research and Treatment of Cancer (EORTC) 30846 trial, the median survival for delayed endocrine treatment was 6.1 year, and for immediate treatment 7.6 year, the HR for survival on delayed versus immediate treatment was 1.23 (95 % CI 0.88–1.71), indicating a 23 % nonsignificant trend in favour of early treatment. In EORTC 30891, the immediate androgen deprivation resulted in a modest but statistically significant increase in overall survival. The protocol SAKK 08/88 showed the lack of any major advantage of immediate compared with deferred hormonal treatment regarding quality of life or overall survival.
Conclusions
The early intervention with hormonal treatment for patients with LAPC provides important reductions in all-cause mortality, prostate cancer-specific mortality, overall progression, and distant progression compared with deferring their use until standard care has failed to halt the disease.
Similar content being viewed by others
Abbreviations
- APC:
-
Advanced prostate cancer
- CAB:
-
Combined androgen blockade
- CI:
-
Confidence interval
- CPA:
-
Cyproterone acetate
- DES:
-
Diethylstilbestrol
- DET:
-
Delayed estrogenic treatment
- EET:
-
Early estrogenic treatment
- EORTC:
-
European Organisation for Research and Treatment of Cancer
- EPC:
-
Early prostate cancer
- HR:
-
Hazard ratio
- LAPC:
-
Locally advanced prostate cancer
- LHRH:
-
Luteinizing hormone-releasing hormone
- MRC:
-
Medical Research Council
- NSAA:
-
Nonsteroidal antiandrogen
- OS:
-
Overall survival
- PC:
-
Prostate cancer
- PFS:
-
Progression-free survival benefit
- PSA:
-
Prostate-specific antigen
- RR:
-
Relative risk
- RTC:
-
Randomized controlled clinical trial
- SEER:
-
Surveillance epidemiology and end results
- VACURG:
-
Veterans Administration Cooperative Urological Research Group
References
Huggins C, Hodges CV (1941) Studies on prostate cancer I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297
Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209
Geller J, Albert J, Vik A (1988) Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 15(Suppl 1):53
Bolla M et al (2004) Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Proc Am Soc Clin Oncol 23(382):4504
Grossfeld GD et al (2003) Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157–163
Catton C et al (2002) Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol 9:1444–1452
Gretzer MB et al (2002) Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. Urology 60:1034–1039
Hull GW et al (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528–534
Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597
National Institute for Health and Clinical Excellence (2002) Guidance on cancer services—improving outcomes in urological cancers: the manual, September
Hope RA, Longmore JM, McManus SK, Wood-Allum C (eds) (1998) Oxford Handbook of Clinical Medicine, 4th edn. Oxford University Press, Oxford
Penson DF, Litwin MS (2003) The physical burden of prostate cancer. Urol Clin North Am 30:305–313
Rosenfeld B et al (2004) Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology 13:800–807
Lintz K et al (2003) Prostate cancer patients’ support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology 12:769–783
Smith MR (2004) Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol 5:367–375
Smith JA Jr, Soloway MS, Young MJ (1999) Complications of advanced prostate cancer. Urology 54(Suppl 6A):8–14
Ullrich PM et al (2003) Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol 169:1449–1452
Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, Oxford
Montreuil B, Bendavid Y, Brophy J (2005) What is so odd about odds? Can J Surg 48:400–402
Egger M, Davey Smith G, Schneider Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
StatsDirect Ltd (2002) Accessed January 2007
Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J Am Med Assoc 143:1317
Veterans Administration Cooperative Urological Research Group, authors (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011
Christensen MM, Aagaard J, Madsen PO (1990) Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur). Prog Clin Biol Res 359:7–14
The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79:235–246
Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group (2000) Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 86(Suppl 3):220, MP6.1.07
Schroder FH et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846—a phase III study. J Urol 172:923–927
Wirth MP et al (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865–1870
Studer UE et al. (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 24(12):1868–1876
Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172:S48–S51
Studer UE et al. (2004) Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 22(20):4109–4118
Nair B, Wilt T, MacDonald R, et al. (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev
Byar DP, Corle DK (1988) Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7:165–170
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prezioso, D., Iacono, F., Romeo, G. et al. Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma. World J Urol 32, 661–667 (2014). https://doi.org/10.1007/s00345-013-1144-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-013-1144-x